Gossamer Bio Inc (NASDAQ:GOSS) CFO Bryan Giraudo bought 1,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The shares were acquired at an average cost of $18.70 per share, for a total transaction of $18,700.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.
GOSS opened at $19.32 on Wednesday. Gossamer Bio Inc has a 52 week low of $15.59 and a 52 week high of $25.06.
Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.27). On average, equities analysts anticipate that Gossamer Bio Inc will post -2.35 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Creative Planning purchased a new stake in Gossamer Bio in the first quarter worth about $260,000. Bank of Montreal Can bought a new position in Gossamer Bio in the first quarter worth about $25,000. Rhumbline Advisers bought a new position in Gossamer Bio in the first quarter worth about $271,000. Victory Capital Management Inc. bought a new position in Gossamer Bio in the first quarter worth about $18,649,000. Finally, Dean Capital Investments Management LLC bought a new position in Gossamer Bio in the first quarter worth about $725,000. 52.76% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Insider Buying: Gossamer Bio Inc (GOSS) CFO Acquires 1,000 Shares of Stock” was posted by WKRB News and is owned by of WKRB News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.wkrb13.com/2019/06/05/insider-buying-gossamer-bio-inc-goss-cfo-acquires-1000-shares-of-stock.html.
Gossamer Bio Company Profile
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.